Agents to treat BRAF-mutant lung cancer
BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC) patients. BRAF V600E mutations account for 50% of these cases, and the remaining BRAF mutations are non-V600E. The biologic behavior of BRAF-mutated lung tumors tends to be more aggressive and resistant to chemotherapy...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioExcel Publishing Ltd
2019-03-01
|
| Colecção: | Drugs in Context |
| Assuntos: | |
| Acesso em linha: | https://drugsincontext.com/agents-to-treat-braf-mutant-lung-cancer |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|